BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9811455)

  • 21. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
    Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
    Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p27kip1-independent cell cycle regulation by MYC.
    Berns K; Martins C; Dannenberg JH; Berns A; te Riele H; Bernards R
    Oncogene; 2000 Oct; 19(42):4822-7. PubMed ID: 11039898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
    Liu Y; Lu C; Shen Q; Munoz-Medellin D; Kim H; Brown PH
    Oncogene; 2004 Oct; 23(50):8238-46. PubMed ID: 15378019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.
    Schreiber M; Muller WJ; Singh G; Graham FL
    Oncogene; 1999 Mar; 18(9):1663-76. PubMed ID: 10208428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. v-Abl utilizes multiple mechanisms to drive G1/S progression in fibroblasts.
    Coutts M; Zou X; Calame K
    Oncogene; 2000 Feb; 19(6):801-9. PubMed ID: 10698498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
    Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
    Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators.
    Morris L; Allen KE; La Thangue NB
    Nat Cell Biol; 2000 Apr; 2(4):232-9. PubMed ID: 10783242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver.
    Luedde T; Rodriguez ME; Tacke F; Xiong Y; Brenner DA; Trautwein C
    Hepatology; 2003 Apr; 37(4):833-41. PubMed ID: 12668976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
    Nakanishi M; Kaneko Y; Matsushime H; Ikeda K
    Biochem Biophys Res Commun; 1999 Sep; 263(1):35-40. PubMed ID: 10486249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deregulated expression of E2F-1 induces cyclin A- and E-associated kinase activities independently from cell cycle position.
    Soucek T; Pusch O; Hengstschläger-Ottnad E; Adams PD; Hengstschläger M
    Oncogene; 1997 May; 14(19):2251-7. PubMed ID: 9178900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
    Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
    Oncogene; 1999 May; 18(21):3290-302. PubMed ID: 10359535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in cell cycle regulation in mouse skin tumors.
    Balasubramanian S; Ahmad N; Jeedigunta S; Mukhtar H
    Biochem Biophys Res Commun; 1998 Feb; 243(3):744-8. PubMed ID: 9500999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cyclin-dependent kinase inhibitors in mammal cells].
    Jiang H; Wang YC
    Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes.
    Mouriaux F; Casagrande F; Pillaire MJ; Manenti S; Malecaze F; Darbon JM
    Invest Ophthalmol Vis Sci; 1998 May; 39(6):876-84. PubMed ID: 9579467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cdk inhibiting proteins].
    Tomoda K; Kato J
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1407-13. PubMed ID: 9309133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms.
    Zhang SY; Liu SC; Goodrow T; Morris R; Klein-Szanto AJ
    Mol Carcinog; 1997 Mar; 18(3):142-52. PubMed ID: 9115584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polyomavirus large T antigen-dependent DNA amplification.
    Stiegler P; Schüchner S; Lestou V; Wintersberger E
    Oncogene; 1997 Feb; 14(8):987-95. PubMed ID: 9050998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
    Khleif SN; DeGregori J; Yee CL; Otterson GA; Kaye FJ; Nevins JR; Howley PM
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4350-4. PubMed ID: 8633069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cell growth control by the E2F transcription factor].
    Ohtani K; Ikeda M
    Tanpakushitsu Kakusan Koso; 1997 Jul; 42(10 Suppl):1603-11. PubMed ID: 9279087
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.